MedTrace Logo

This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and 10 Years Later, in Children Who Had Received Havrix at Selected Health Centres of Panama

NCT02712359 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1201

Last updated 2019-11-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the persistence of hepatitis A antibodies, approximately 8 years and 10 years post vaccination with the complete series of Havrix (2 doses) and the partial series completion (1 dose).

Conditions

  • Hepatitis A Vaccine

Interventions

OTHER

Blood sample collection

A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-01
Primary Completion
2018-08-22
Completion
2018-08-22

Countries

  • Panama

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02712359 on ClinicalTrials.gov